Liposome gets Swiss okay on fungal drug . Liposome Co Inc said it has received approval for Abelcet in Switzerland as a first - line treatment of candidiasis and for the treatment of severe systemic fungal infections in patients who have not responded to or are intolerant of conventional therapy . The company said it now has direct access to about 75 percent of the total European market opportunity for this class of drug . 
